#Train simulator 2014 free trial trial
Leveraged to support strategic decision-making, the Simulator provides valuable information for designing clinical trials, to reduce trial size and complexity and to obtain clinical trial waivers.For early pharmacokinetic determination of first-in-human dosing and to answer other translational questions.The Simcyp Simulator is employed across the drug development cycle: In the last decade, PBPK modeling and simulation has soared in its use and applicability-Simcyp, working with its industry, academic and regulatory partners has led the way. Expansion of the Human Brain Model to 5 Compartments.The Simulator includes a unique set of genetic, physiological and epidemiological databases that facilitate simulating virtual populations with different demographics and ethnicities. The concentration of the drug in each compartment is determined by combining systems data, drug data, and trial design information. Simcyp PBPK models describe the behavior of drugs in different body tissues, with each tissue considered a physiological compartment. Links in vitro data to in vivo absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic / pharmacodynamic (PK/PD) outcomes to explore clinical scenarios and support drug development decisions.An unmatched body of science, the Simulator includes 10 advanced mechanistic organs, 25 sub-populations, and 100+ compound files for use by member companies.The Simulator includes with extensive libraries on demographics, developmental physiology and the ontogeny of drug elimination pathways.Simcyp is being applied to small molecules, biologics, ADCs, generics, and new modality drugs. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated physiologically based pharmacokinetics (PBPK) platform for determining first-in-human dosing, optimizing clinical study design, evaluating new drug formulations, setting the dose in untested populations, performing virtual bioequivalence analyses, and predicting drug-drug interactions (DDIs). Predict Drug Performance from Virtual Populations